Evaluating the effect of intravenous hydrocortisone, methylprednisolone, and dexamethasone in treatment of patients with moderate to severe acute respiratory distress syndrome caused by COVID-19

Phase 2

• Conditions: COVID-19.; COVID-19, virus identified; U07.1

• Registration Number: IRCT20120215009014N354
• Lead Sponsor: Hamedan University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 2 May 2022

Recruitment & Eligibility

• Status: Complete
• Sex: All
• Target Recruitment: 81

Inclusion Criteria

Age of 18 to 70 years,
Hospitalized in intensive care unit in less than past 48 hours,
Mild to moderate acute respiratory distress syndrome due to COVID-19,
Bilateral pulmonary infiltration in chest X-ray or CT-scan,
Respiratory distress with more than 24 breathe per minute

Exclusion Criteria

Pregnancy or breastfeeding,
Cardiopulmonary edema,
Severe acute respiratory distress syndrome,
Using antioxidant drugs,
Chronic liver or renal disease,
Contraindication of N-acetyl cysteine

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
eed to mechanical ventilation. Timepoint: Within 28 days after the intervention. Method of measurement: By physical examination.;The patient's clinical status. Timepoint: Within 28 days after the intervention. Method of measurement: Based on the World Health Organization's 7-score system.;Mortality rate. Timepoint: Within 28 days after the intervention. Method of measurement: Based on medical document.